Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma

Rapamycin is known to inhibit the mammalian target of rapamycin complex (mTORC)1 signaling pathway, but it is unable to effectively inhibit mTORC2, resulting in activation of protein kinase B in multiple myeloma (MM) cell lines. Additionally, certain studies have suggested that resveratrol has an ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Hong-Guang, Wu, Guo-Zhen, Wu, Guo-Hua, Bao, Yong-Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920858/
https://www.ncbi.nlm.nih.gov/pubmed/29731844
http://dx.doi.org/10.3892/ol.2018.8178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920858/
https://www.ncbi.nlm.nih.gov/pubmed/29731844
http://dx.doi.org/10.3892/ol.2018.8178

Ejemplares similares